Search clinical trials for: Adult vaccines

Total 27993 results

Sanofi Pasteur, a Sanofi Company
Immune Design

Terminated

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 (HSV15)

Genital Herpes

United States
Pontificia Universidad Catolica de Chile
Sinovac Biotech Co., Ltd; Ministry of Health, Chile

Active, not recruiting

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)

Covid19 | Vaccines

Chile
Merck Sharp & Dohme LLC

Completed

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

Pneumonia, Pneumococcal

United States
Themis Bioscience GmbH
Walter Reed Army Institute of Research (WRAIR)

Completed

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

Chikungunya Virus Infection

Puerto Rico
PATH

Completed

Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults

Polio

Belgium
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
Icon Genetics GmbH
University Hospital, Ghent

Completed

Recombinant, Bivalent, Norovirus Vaccine Study

Norovirus

Belgium
Jiangsu Province Centers for Disease Control and...
CanSino Biologics Inc.

Completed

Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults

COVID-19

China
Sinovac Research and Development Co., Ltd.

Suspended

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey

COVID-19

Turkey
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

HIV Infections

United States, Peru
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults (M&M)

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

HIV Infections

United States, Peru
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
Sanofi

Completed

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

Pneumoccocal Immunisation

United States
Albert B. Sabin Vaccine Institute
ICON plc; Oklahoma Blood Institute

Completed

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Ebola Virus Disease | Marburg Virus Disease

United States
PT Bio Farma

Completed

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Hepatitis B

Indonesia
VBI Vaccines Inc.

Completed

A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

Hepatitis B

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Vanderbilt University Medical Center

Completed

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Flu Vaccine

United States
Assistance Publique - Hôpitaux de Paris
COVIREIVAC

Active, not recruiting

Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination (COVIBOOST)

COVID-19 | Vaccine Reaction

France
Pfizer

Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

United States
Mahidol University
Clinixir Co., Ltd.; Program Management Unit-C (PMU-C), governed by Ministry...

Completed

Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine

COVID-19 Infection | COVID-19 VACCINE

Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
University of Oxford
Imperial College London; KEMRI-Wellcome Trust Collaborative Research Program; University of Nairobi and other collaborators

Active, not recruiting

A Study to Test Three Experimental HIV Vaccines in Healthy Adults. (HIV-CORE 006)

HIV-1-infection

Kenya, Uganda, Zambia
Novavax

Withdrawn

Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

Covid19

Australia
HIV Vaccine Trials Network
National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention...

Completed

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

COVID-19 | SARS-CoV-2

United States, Zimbabwe, Malawi, Peru, South Africa, Zambia
International AIDS Vaccine Initiative
GlaxoSmithKline; George Washington University; Amsterdam UMC, location VUmc; Rockefeller...

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

HIV Infections

United States, Netherlands
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
ModernaTX, Inc.

Completed

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

SARS-CoV-2

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults (VYF01)

Yellow Fever (Healthy Volunteers)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
University of Oxford

Completed

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

Chikungunya | Zika

Mexico
Janssen Vaccines & Prevention B.V.

Completed

Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

Human Immunodeficiency Virus

Thailand
Suping Wang
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults (HIV)

Hepatitis B Vaccine
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Beth Israel Deaconess Medical Center; US Military HIV Research Program; Ragon...

Completed

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Human Immunodeficiency Virus

United States
Epicentre
Kenya Medical Research Institute

Completed

Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) (YEFE)

Yellow Fever

Uganda, Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali

Malaria

Mali
National Cancer Institute (NCI)

Completed

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Adolescent | Human Immunodeficiency Virus | Papillomavirus Vaccines | Human Papillomavirus- 6, 11, 16, 18

United States
BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany
CureVac

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Rabies

Belgium, Germany
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Genexine, Inc.

Active, not recruiting

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

SARS-CoV-2

Korea, Republic of
Novavax

Completed

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

Respiratory Syncytial Viruses

Australia

3

Subscribe